In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2 - Wikidata - wikimedia - TriplyDB

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

http://www.wikidata.org/entity/Q35083423

about

Foamy-like endogenous retroviruses are extensive and abundant in teleosts The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.Susceptibility of porcine endogenous retrovirus to anti-retroviral inhibitors.MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy.Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Bovine Lactoferrampin, Human Lactoferricin, and Lactoferrin 1-11 Inhibit Nuclear Translocation of HIV Integrase.HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update.

P2860

Q28584468-AB59DEA7-687A-48E7-A48C-1C9BF88620D6 Q36290647-F6EAB757-E2DE-4066-B015-4FF444D44EBB Q36917438-84581B6B-46E3-4D28-8A2F-B7D4A696438C Q38755690-FACF7DAA-DB86-4FA9-B84F-91A08A5BC69B Q38934689-C425F501-D646-4D40-924F-0B9547407195 Q40261719-DF7D8616-D8F9-479E-A60B-B46BDBDF1DDF Q40829357-2D0B47E4-91D6-4F96-A515-9C0F745C3DEC Q50993098-EB80156E-F77A-40F6-B409-0619A91909DA

P2860

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

http://www.wikidata.org/entity/Q35083423

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

In vitro activity of dolutegra ...... rase inhibitor-resistant HIV-2

@ast

In vitro activity of dolutegra ...... rase inhibitor-resistant HIV-2

@en

type

label

In vitro activity of dolutegra ...... rase inhibitor-resistant HIV-2

@ast

In vitro activity of dolutegra ...... rase inhibitor-resistant HIV-2

@en

prefLabel

In vitro activity of dolutegra ...... rase inhibitor-resistant HIV-2

@ast

In vitro activity of dolutegra ...... rase inhibitor-resistant HIV-2

@en

P1433

Q35083423-CEF6F82C-A1FC-4F32-B5EB-5D773BCC3793

P1476

Q35083423-298644BB-458E-4255-B612-2BAD02BEC047

P2093

Q35083423-1C794579-157C-455F-A602-C868DEA05C27

Q35083423-2230D1A4-675C-4D3F-A398-BC31C851AA31

Q35083423-41BA0396-AF43-4FBF-95EE-006498D8EC35

Q35083423-440F2435-7026-4C82-BC89-82FB936D8FFA

Q35083423-4C021961-2E10-461A-9997-73EEF344BCD9

Q35083423-97EDA064-7698-4819-AF87-C2ACA53DCB58

Q35083423-FA2B5BB4-FBB2-49C2-9D86-86B2C247502E

P2860

Q35083423-0EB06B3B-B99F-4F15-8C95-35FB431F86CF

Q35083423-0FE53435-47D4-46FA-8CB6-76ADD8E8E21E

Q35083423-1370E5AC-B05D-4D3F-B2FE-90690377F4D9

Q35083423-17CF9824-4A43-4DE9-BAF5-D46CEB08FBFF

Q35083423-1CB09C58-A9B6-4E8B-A855-D164086ED8B1

Q35083423-1F123472-A735-4017-ABDA-B1BF83236369

Q35083423-2AE2A259-4188-4787-A6BD-715CF44AE20A

Q35083423-2C2901D9-3433-4F80-81C8-919510E185C4

Q35083423-2CED4776-FFB2-4E69-89EF-8333F5935F74

Q35083423-2EFB994D-881E-4983-A07C-D77AF76DDE82

P2888

Q35083423-6E411C35-F36D-49EE-B591-7B5C9BEE058B

P304

Q35083423-E4807278-A65F-469F-ABC1-C9F261934778

P31

Q35083423-FCB8C18A-CEFA-4CE5-AC7F-3C271E817644

P356

Q35083423-24AA14DE-D959-4090-A6E7-5E61E1BE4928

P478

Q35083423-0426959C-7C4B-45D1-AB96-6E9BC3D1CF0D

P50

Q35083423-DD2FB128-7C0E-42A1-9062-F34B499D5485

P577

Q35083423-283E2610-6563-4E61-B7C1-145FEFEF9025

P5875

Q35083423-52B7EB89-6997-4719-A190-08C7DD475103

P6179

Q35083423-53F06255-5C90-4607-ABF6-3D6F6937C809

P698

Q35083423-FC90D03B-1F31-4AC6-BC8A-9EEA9DDF6D69

P932

Q35083423-5A0CCF87-65AF-4671-B5F0-4DDBEB938312

P356

S12977-015-0146-8

P1433

P1476

In vitro activity of dolutegra ...... rase inhibitor-resistant HIV-2

@en

P2093

Charlotte Pan

http://www.w3.org/2001/XMLSchema#string

Dana N Raugi

http://www.w3.org/2001/XMLSchema#string

James I Mullins

http://www.w3.org/2001/XMLSchema#string

Moussa Seydi

http://www.w3.org/2001/XMLSchema#string

Papa Salif Sow

http://www.w3.org/2001/XMLSchema#string

Robert A Smith

http://www.w3.org/2001/XMLSchema#string

University of Washington-Dakar HIV-2 Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 integrase inhibitor resistance and its clinical implications

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations

HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4⁺ cell counts

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

Genotypic resistance profiles of HIV-2-treated patients in West Africa.

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens

P2888

s12977-015-0146-8

P304

10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12977-015-0146-8

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Geoffrey S. Gottlieb

P577

2015-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272398697

http://www.w3.org/2001/XMLSchema#string

P6179

1031755243

http://www.w3.org/2001/XMLSchema#string

P698

25808007

http://www.w3.org/2001/XMLSchema#string

P932

4328052

http://www.w3.org/2001/XMLSchema#string